Connect with us

Health

Bill Gates reveals 'next phase of Alzheimer's fight' as he shares dad's personal battle

Published

on

Bill Gates reveals 'next phase of Alzheimer's fight' as he shares dad's personal battle

NEWYou can now listen to Fox News articles!

Bill Gates is speaking out about his personal experience with Alzheimer’s — and his hope for progress in fighting the disease.

In an essay published this week on his blog at GatesNotes.com, the Microsoft co-founder and tech billionaire, 69, reflected on the difficulty of spending another Father’s Day without his dad, Bill Gates Sr.

The elder Gates passed away in 2020 at the age of 94 after battling Alzheimer’s.

RATES OF DEMENTIA ARE LOWER IN PEOPLE WHO EAT THIS SPECIFIC DIET, RESEARCH SHOWS

Advertisement

“It was a brutal experience, watching my brilliant, loving father go downhill and disappear,” Gates wrote in the blog post.

Today, motivated by his own experience with the common dementia, Gates — who serves as chair of the Gates Foundation — is committed to working toward a cure for the common dementia, which currently affects more than seven million Americans, or one in nine people over 65.

Bill Gates and Bill Gates Sr. pose in a meeting room at the Seattle headquarters of the Bill & Melinda Gates Foundation in 2008. (Gates Ventures)

In his blog, Gates expressed optimism about the “massive progress” being made in the fight against Alzheimer’s and other dementias.

Last year, Gates said he visited Indiana University’s School of Medicine in Indianapolis to tour the labs where teams have been researching Alzheimer’s biomarkers.

Advertisement

BILL GATES LIKELY HAD AUTISM AS A CHILD, HE REVEALS: ‘WASN’T WIDELY UNDERSTOOD’

“I also got the opportunity to look under the hood of new automated machines that will soon be running diagnostics around the world,” he wrote. “It’s an exciting time in a challenging space.”

One of the biggest breakthroughs in Alzheimer’s research, according to Gates, is blood-based diagnostic tests, which detect the ratio of amyloid plaques in the brain. (Amyloid plaques, clumps of protein that accumulate in the brain, are one of the hallmarks of Alzheimer’s.)

Bill Gates Jr. (right) poses with his father at his graduation ceremony in 1973. (Gates family)

“I’m optimistic that these tests will be a game-changer,” Gates wrote. 

Advertisement

Last month, the U.S. Food and Drug Administration (FDA) approved the first blood-based test for patients 55 years and older, as Fox News Digital reported at the time.

“A simple, accurate and easy-to-run blood test might one day make routine screening possible.”

Traditionally, Gates noted, the primary path to Alzheimer’s diagnosis was either a PET scan (medical imaging) or spinal tap (lumbar puncture), which were usually only performed when symptoms emerged.

The hope is that blood-based tests could do a better job of catching the disease early, decline begins.

The Gates family poses for a photo in 1965. The elder Gates passed away in 2020 at the age of 94 after battling Alzheimer’s. (Gates family)

Advertisement

“We now know that the disease begins 15 to 20 years before you start to see any signs,” Gates wrote. 

“A simple, accurate and easy-to-run blood test might one day make routine screening possible, identifying patients long before they experience cognitive decline,” he stated.

Gates said he is often asked, “What is the point of getting diagnosed if I can’t do anything about it?”

To that end, he expressed his optimism for the future of Alzheimer’s treatments, noting that two drugs — Lecanemab (Leqembi) and Donanemab (Kisunla) — have gained FDA approval.

Advertisement

“Both have proven to modestly slow down the progression of the disease, but what I’m really excited about is their potential when paired with an early diagnostic,” Gates noted.

Alzheimer’s disease currently affects more than seven million Americans, or one in nine people over 65. (iStock)

He said he is also hopeful that the blood tests will help speed up the process of enrolling patients in clinical trials for new Alzheimer’s drugs.

To accomplish this, Gates is calling for increased funding for research, which often comes from federal grants.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Advertisement

“This is the moment to spend more money on research, not less,” he wrote, also stating that “the quest to stop Alzheimer’s has never had more momentum.”

“There is still a huge amount of work to be done — like deepening our understanding of the disease’s pathology and developing even better diagnostics,” Gates went on. 

“I am blown away by how much we have learned about Alzheimer’s over the last couple of years.”

Gates pointed out that when his father had Alzheimer’s, it was considered a “death sentence,” but that is starting to change.

“I am blown away by how much we have learned about Alzheimer’s over the last couple of years,” he wrote.

Advertisement

For more Health articles, visit www.foxnews.com/health

“I cannot help but be filled with a sense of hope when I think of all the progress being made on Alzheimer’s, even with so many challenges happening around the world. We are closer than ever before to a world where no one has to watch someone they love suffer from this awful disease.”

Advertisement

Health

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier

Published

on

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier


Advertisement





How To Curb Late-Night Cravings and Make Weight Loss Easier | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

Published

on

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

NEWYou can now listen to Fox News articles!

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge.

Advertisement

That’s according to new research from the University of California San Diego, which found that a specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk.

The researchers analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study in the late 1990s, according to the study’s press release. 

KEY FITNESS MEASURE IS STRONG PREDICTOR OF LONGEVITY AFTER CERTAIN AGE, STUDY FINDS

The women ranged from 65 to 79 years of age and showed no signs of cognitive decline at the start of the study.

After tracking the participants for up to 25 years, the researchers concluded that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with future mild cognitive impairment and dementia. 

Advertisement

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge. (iStock)

Women who had higher levels of p-tau217 at the beginning of the study were “much more likely” to develop the disease. The findings were published today in JAMA Network Open.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” first author Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine, told Fox News Digital. 

“These biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia.”

“Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin,” he added.

Advertisement

This long lead time could open the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life, according to Shadyab.

A specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk. (iStock)

“As the research advances, these biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia,” he said.

This risk relationship wasn’t the same across the board, however. Women over 70 with higher p-tau217 levels had “poorer cognitive outcomes” compared to those under 70, as did those with the APOE ε4 gene, which is a known risk factor for Alzheimer’s disease.

Advertisement

The study also found that p-tau217 was a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy compared to those who received a placebo.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” said senior author Linda K. McEvoy, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, in the release. 

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” a researcher said. (iStock)

“This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Advertisement

Blood tests for Alzheimer’s disease are still being studied and are not recommended for routine screening in people without symptoms, Shadyab noted. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

More research is needed before this approach can be considered for clinical use prior to cognitive symptoms. 

Future studies should investigate how other factors — like genetics, hormone therapy and age-related medical conditions — might interact with plasma p-tau217, the researchers added.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

“The study examined only older women, so the findings may not necessarily apply to men or younger populations,” Shadyab noted. “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”

Continue Reading

Health

Key fitness measure is strong predictor of longevity after certain age, study finds

Published

on

Key fitness measure is strong predictor of longevity after certain age, study finds

NEWYou can now listen to Fox News articles!

For women over 60, muscle strength plays a critical role in longevity, a new study confirms.

Researchers at the University at Buffalo, New York, followed more than 5,000 women between the ages of 63 and 99, finding that those with greater muscle strength had a significantly lower risk of death over an eight-year period.

The findings were published in JAMA Network Open.

EXERCISE AFFECTS THE HEART IN A HIDDEN, POWERFUL WAY BY REWIRING NERVES, STUDY FINDS

Advertisement

Muscle function was measured using grip strength and how quickly participants could complete five unassisted sit-to-stand chair raises. 

These are two tests commonly used in clinical settings to evaluate muscle function in older adults, the researchers noted.

A recent study shows that stronger muscle strength in women over 60 is linked to a lower risk of death over eight years. (iStock)

“In a community cohort of ambulatory older women, muscular strength was associated with significantly lower mortality rates, even when we accounted for usual physical activity and sedentary time measured using a wearable monitor, gait speed and blood C-reactive protein levels,” study lead author Michael LaMonte, research professor of epidemiology and environmental health at the University at Buffalo, told Fox News Digital.

“Movement is the key — just move more and sit less.”

Advertisement

Many earlier studies did not include those objective measurements, making it difficult to determine whether muscle strength itself was linked to longevity, according to LaMonte. “Our study was able to better isolate the association between strength and death in later life,” he added.

Even for women who don’t get the recommended amount of aerobic physical activity, which is at least 150 minutes per week, muscle strength remained important for longevity, the researchers found.

Women with greater muscle strength were more likely to live longer, even if they did not meet the recommended amount of aerobic exercise. (iStock)

“The findings of lower mortality in those who had higher strength but were not meeting current national guidelines on aerobic activity were somewhat intriguing,” LaMonte said.

Advertisement

CLICK HERE FOR MORE LIFESTYLE STORIES

Federal guidelines recommend strengthening activities one to two days per week, targeting major muscle groups.

Resistance training does not have to require a gym membership, LaMonte noted. These exercises can be performed using free weights, resistance bands, bodyweight movements or even household items, such as soup cans.

Experts recommend working major muscle groups one or two days a week using weights, bands or bodyweight exercises. (iStock)

“Movement is the key — just move more and sit less,” he said. “When we can no longer get out of the chair and move around, we are in trouble.”

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

LaMonte acknowledged several limitations of the study. The researchers assessed muscle strength in older age but did not explore how earlier levels in adulthood might influence long-term health outcomes.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“We were not able to understand how strength and mortality relate in younger ages,” he said, noting that future research should explore whether building strength earlier could have an even greater impact on longevity.

Advertisement
Continue Reading
Advertisement

Trending